Smiths Group plc

Public consensus   -   Last updated 07/02/19

Reporting currency: GBP
Reporting unit: Absolute
 
NO. OF
FORECASTS
FY19
CONSENSUS
07/02/19
FY19
MIN
FY19
MAX
Smiths Group plc
Revenue (£ Millions)
John Crane
12
927
904
961
Medical
12
898
888
912
Detection
12
827
809
843
Interconnect
12
312
303
320
Flex-Tek
12
392
372
491
Total Revenue
12
3,355
3,291
3,426
Operating Profit (£ Millions)
John Crane
12
214
207
221
Medical
12
159
152
165
Detection
12
139
131
147
Interconnect
12
45
41
47
Flex-Tek
12
74
70
92
Corporate
12
(59)
(63)
(55)
Total Operating Profit
12
572
559
585
Operating Margin %
John Crane
12
23.0
22.6
23.5
Medical
12
17.7
16.9
18.5
Detection
12
16.8
16.0
17.6
Interconnect
12
14.3
13.3
14.9
Flex-Tek
12
18.9
18.5
19.4
Total - Operating Margin
12
17.0
16.8
17.4
Net financing
12
(55)
(65)
(49)
PBT
12
516
504
528
Tax rate
10
25.0
24.5
25.2
Tax
10
(129)
(133)
(126)
Net Income
11
388
378
397
Number of shares
11
396.84
395.69
402.00
EPS (p)
11
97.83
94.51
100.31
DPS (p)
12
46.29
45.44
47.78
Change in WC
6
(24)
(85)
27
D&A
6
126
97
145
Operating CF
5
519
407
629
FCF
5
315
241
422
Net debt
9
507
(975)
1,035
GBP/EUR
6
1.21
1.12
1.31
GBP/USD
6
1.21
1.12
1.29

Disclaimer

* Headline profit is before exceptional items, amortisation and impairment of acquired intangible assets and financing gains/losses from currency hedging.
* The United Flexible acquisition which is expected to complete in H2 2019 has not been included in the consensus. Analysts 's forecasts that included it have been adjusted for.

Each line is the average for the analysts' forecasts for that item and as such the numbers do not always total correctly because of rounding differences.

The forecasts in this analysis have been gathered from a number of registered investment analysts and are, as such, publicly available information. These estimates are forward looking and are therefore subject to risks and uncertainties that may materially affect eventual results. In distributing this analysis, Smiths Group does not imply its endorsement of, or concurrence with, such information, conclusions or recommendations. Nothing in this analysis should be taken as a recommendation to buy or sell shares in Smiths Group or to take any other action or place any reliance on the analysis. Smiths Group is not regulated by the Financial Conduct Authority and cannot offer investment advice.

Although Smiths Group will endeavour to procure that the information is kept updated, Smiths Group assumes no obligation to update or revise such information to reflect circumstances existing after the date hereof. Neither Smiths Group nor any subsidiary undertaking or any director, officer or employee of Smiths Group accepts any responsibility for the accuracy of the forecasts used in this analysis and therefore shall have no liability whatsoever for the consequences of any reliance or actions taken or not taken based on any of the information in this analysis.